Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study
By stratifying patients based on Ct.Th changes, we identified treatment responders (56%) with rapid cortical bone improvements detectable at 6 monthsIdentifying clinical predictors of ROMO responsiveness and determining whether shorter treatment durations may be justified in selected patients warrant further investigation.
Authors
- Mariana Gonzalez Pernas
- María Belén Zanchetta
- Fernando Jerkovich
- Luciana Erdociain
- José Rubén Zanchetta
- Nadia Schwartz
- Jesica Pingel
Institutions
- Universidad del Salvador (AR)
- Instituto de Diagnóstico e Investigaciones Metabólicas (AR)
Publication Details
- Journal
- Bone Reports
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1016/j.bonr.2026.101902
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00